| I-21 Muriel Boulton Exposure-Response (E-R) analysis of efficacy and safety of niraparib/abiraterone acetate combination in patients with metastatic castration-resistant prostate cancer Wednesday 10:00-11:30 |
| I-21 Muriel Boulton Exposure-Response (E-R) analysis of efficacy and safety of niraparib/abiraterone acetate combination in patients with metastatic castration-resistant prostate cancer Wednesday 10:00-11:30 |